CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...